> Detailanzeige

Glauche, Ingmar [Verfasser:in]; Kuhn, Matthias [Verfasser:in]; Baldow, Christoph [Verfasser:in]; Schulze, Philipp [Verfasser:in]; Rothe, Tino [Verfasser:in]; Liebscher, Hendrik [Verfasser:in]; Roy, Amit [Verfasser:in]; Wang, Xiaoning [Verfasser:in]; Roeder, Ingo [Verfasser:in]

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
  • Beteiligte: Glauche, Ingmar [Verfasser:in]; Kuhn, Matthias [Verfasser:in]; Baldow, Christoph [Verfasser:in]; Schulze, Philipp [Verfasser:in]; Rothe, Tino [Verfasser:in]; Liebscher, Hendrik [Verfasser:in]; Roy, Amit [Verfasser:in]; Wang, Xiaoning [Verfasser:in]; Roeder, Ingo [Verfasser:in]
  • Erschienen: London: Macmillan Publishers Limited, part of Springer Nature, [2018]
  • Erschienen in: Scientific Reports ; 8,1, (2018)
  • Sprache: Englisch
  • DOI: 10.1038/s41598-018-29923-4
  • RVK-Notation: UA 1000 : Referateblätter und Zeitschriften
  • Schlagwörter: Publishing Fund ; BCR-ABL-Transkriptniveaus ; Tyrosinkinase-Inhibitoren (TKI) ; Stammzelldynamik ; tyrosine kinase inhibitors (TKI) ; Behandlungsoptimierungen ; Publikationsfond ; BCR-ABL transcript levels ; Technische Universität Dresden
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Longitudinal monitoring of BCR-ABL transcript levels in peripheral blood of CML patients treated with tyrosine kinase inhibitors (TKI) revealed a typical biphasic response. Although second generation TKIs like dasatinib proved more efficient in achieving molecular remission compared to first generation TKI imatinib, it is unclear how individual responses differ between the drugs and whether mechanisms of drug action can be deduced from the dynamic data. We use time courses from the DASISION trial to address statistical differences in the dynamic response between first line imatinib vs. dasatinib treatment cohorts and we analyze differences between the cohorts by fitting an established mathematical model of functional CML treatment to individual time courses. On average, dasatinib-treated patients show a steeper initial response, while the long-term response only marginally differed between the treatments. Supplementing each patient time course with a corresponding confidence region, we illustrate the consequences of the uncertainty estimate for the underlying mechanisms of CML remission. Our model suggests that the observed BCR-ABL dynamics may result from different, underlying stem cell dynamics. These results illustrate that the perception and description of CML treatment response as a dynamic process on the level of individual patients is a prerequisite for reliable patient-specific response predictions and treatment optimizations.
  • Zugangsstatus: Freier Zugang
  • Rechte-/Nutzungshinweise: Namensnennung (CC BY)